

Hematology Oncology Grand Rounds
Course No. 27D12
Friday, August 21, 2026
12:00-1:00 PM CST

***** ZOOM PRESENTATION *****

[Join Zoom Meeting](#)

Meeting ID 935 6856 6712

Passcode 08625485

“Decoding Anti-Tumor Immunity in kidney Cancer”

Presented by:

David Braun, MD, PhD

Department of Medicine, Yale Cancer Center, Yale School of Medicine – New Haven, CT

Accreditation Statement: The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

The University of Oklahoma is an equal opportunity institution. www.ou.edu/eoo

Accommodation Statement: For accommodations, please contact Tavana Traylor (tovana-n-traylor@ou.edu)

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Disclosure & Mitigation Report

Role(s)	First Name	Last Name	Ineligible Company	Nature of the Financial Relationship
Course Director	Mohammad	Khawandanah, MD	I have no financial relationships or affiliations with ineligible companies to disclose.	
Course Contact	Tovana	Traylor	I have no financial relationships or affiliations with ineligible companies to disclose.	
Interim Planner / Moderator	Raid	Aljumaily, MD	I have no financial relationships or affiliations with ineligible companies to disclose.	
Planner / Moderator	Yubin	Kang, MD	I have no financial relationships or affiliations with ineligible companies to disclose.	
Planner	Nishant	Tiwari, MD	I have no financial relationships or affiliations with ineligible companies to disclose.	
Speaker	David	Braun, MD, PhD	Elephas	DAB reports share options
			AstraZeneca and Exelixis	Research Support
			AbbVie; Accolade 2nd MD; Adnovate Strategies; Aptitude Health; ASCO Post and Harborside; AVEO; Calico; Cancer Expert Now; CancerNetwork; Caris; Catenion; Cello Health	Advisory Board, Consulting Fee, Personal Fee

Role(s)	First Name	Last Name	Ineligible Company	Nature of the Financial Relationship
			BioConsulting; Compugen; Curio Science; Daiichi Sankyo; Dechert; DLA Piper; Eisai; Elephas; Exelixis; Haymarket Medical Network; Kainova; LG Chem; Link Cell Therapies; MD Education; MDedge; MedScape; Merck; NeoMorph; Nimbus; OncLive; Ottimo Pharma; Pfizer; PWW Consulting; Scholar Rock; and Targeted Oncology	